Site search
Correspondence address
310 Mira Street, Stavropol, Russia, 355017
Tel
+7 865 2352511, +7 865 2353229.
E-mail
medvestnik@stgmu.ru
The journal is included into The list of leading scientific periodicals.
The journal is included into VINITI database and is registered in Electronic scientific library.
The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.
As shown by modern literature data, the time factor plays an important role in the pharmacodynamics of lithium used for the treatment of bipolar affective disorder (BAD). Its chronotropic properties may depend on the effect on the function of suprachiasmatic nuclei of the hypothalamus, as well as inhibition of glycogen synthase-3 kinase and the mobilization of the epiphyseal hormone melatonin.
References:
1. Arushanian E. B. Jurn. Vysh. Nerv. Dejat. – J. High Nerv. Activ. 1996;46:16-22.
2. Arushanian E. B. Med. Vestn. Sev. Kavkasa. – Med. News of North Caucasus. 2007;6:3-16.
3. Arushanian E. B. Unicalny melatonin. Stavropol, 2007.
4. Arushanian E. B. Jurn. Vysh. Nerv. Dejat. – J. High Nerv. Activ. 2011;61:645-659.
5. Arushanian E. B. Hronopatologia i hronomedizina. – Chronopathol. and chronomed. 2012:122-140.
6. Arushanian E. B. Eksper. I clin. Pharmacol. – Exper. Clin. Pharmacol. 2012;75:44-49.
7. Arushanian E. B., Ovanesov K. B. Jurn. Vysh. Nerv. Dejat. – J. High Nerv. Activ. 1991;41:822-827.
8. Markova N. A., Shvezova E. F. Patogenes. – Pathogenesis. 2013;11:4-8.
9. Abe M., Herzog E. D., Block G. S. Neurorport. 2000;11:3261-3264.
10. Abreu T., Braganca M. J. Affect. Disord. 2015;185:219-229.
11. Anderson G., Maes M. Pharm. Res. 2014;20:3812-3847.
12. Bellivier F., Geoffroy P. A., Etan B. Expert. Opin. Ther. Targets. 2015;19:747-763.
13. Besing R. C., Paul J. R., Habitz L. M. [et al.] J. Biol. Rhythms. 2015;30:155-160.
14. Crofton E. J., Nenov M. N., Zhang Y. Neuropharmacology. 2017;117:49-60.
15. Etan B., Dumaine A., Bellivier F. Hum. Mol. Genet. 2012;21:4030-4037.
16. Fomaro M., McCarthy M. J., De Berardis D. Neuropsychiatry Dis. Treat. 2013;9:243-251.
17. Geoffroy P. A., Curis E., Courtin C. World J. Biol. Psychiatry. 2017;16:1-31.
18. Geoffroy P. A., Etan B., Franchi J. A. Curr. Pharm. Des. 2015;21:3352-3358.
19. Geoffroy P. A., Samalin L., Lorca P. J. Affect. Disord. 2016;204;32-39.
20. Gonzalez R. J. Clin. Psychiatry. 2014;75:323-333.
21. Iwahana E., Akiyama M., Miyakawa K. Eur. J. Neurosci. 2004;19:2281-2287.
22. Jope R. S., Roh M. S. Curr. Drug Targets. 2006;7:1421-1434.
23. Kaladchibachi S. A., Doble B., Anthonopoulos N. J. Circadian. Rhythms. 2007;5:3-10.
24. Kinoshita C., Miyazaki K., Ishida N. Neuroreport. 2012;23:98-102.
25. Luca A., Calandia C., Luca M. Oxid. Med. Cell Longev. 2016;30:547-550.
26. McClung C. A., Cold. Spring Harb. Symp. Quant. Biol. 2007;72:637-644.
27. Milhiet V., Boudebesse C., Bellivier F. Front. Biosci. 2014;6:120-137.
28. Moreira J., Geoffroy P. A. Chronobiol. Int. 2016;33:351-373.
29. Murray G., Harvey A. Bipol. Disord. 2010;12:459-472.
30. Nierenberg A. A. Psychother. Psychosom. 2009;78:391-393.
31. Reiter R. J., Calvo J. R., Karbownik K. H. Ann. N.Y. Acad. Sci. 2000;917:376-386.
32. Seggie J., Westiuk E. S, Grota L. Prog. Neuropharmacol. Biol. Psychiatry. 1987;11:325-334.
33. Souza L. G., Wilhelm E. A., Bortrolatto C. F. Behav. Brain Res. 2014;271:316-324.
34. Valvassori S. S., Dal-Pint G. C., Resende W. R. Neuropharmacology. 2016;24:282-290.
35. Valvassori S. S., Rezin G. T., Ferreira C. L. J. Psychiatry Res. 2010;44:903-909.
Keywords: lithium, bipolar affective disorder, melatonin